Background/aim Patients with atrial fibrillation (AF) and coronary stenting had a poor prognosis. This study aimed to assess the accuracy of CHA 2 DS 2 -VASc score for predicting and grading adverse clinical outcomes in this population. Materials and methods We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA 2 DS 2 -VASc score, ≦ 2 points, 2) Intermediate score, 3–4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, repeat revascularization and ischemic stroke/systemic thromboembolism (IS/SE). Results A total of 2394 patients (men: 72.3% vs. women: 27.7%, median age: 67 years) were included, with the CHA 2 DS 2 -VASc score of 3.6 ± 1.6. The median follow-up duration was 36.2 months. All-cause mortality increased 3 folds from the low score (4.8%) to the high score group (15.8%). The high score group had more IS/SE (7.4%) and MACCE (26.3%). The CHA 2 DS 2 -VASc score ≧ 5 points was independently associated with all-cause death (hazard ratio [HR]: 2.303, 95% confidence interval [CI]: 1.492–3.555), IS/SE (HR: 4.169, 95% CI: 2.216–7.845) and MACCE (HR: 1.468, 95% CI: 1.113–1.936) on multivariate Cox proportional hazards regression. The area under the receiver operating characteristic curve of the CHA 2 DS 2 -VASc score was 0.644 (95% CI: 0.624–0.663) for all-cause death, 0.647 (95% CI: 0.627–0.666) for IS/SE, and 0.592 (95% CI: 0.572–0.611) for MACCE. Conclusion CHA 2 DS 2 -VASc score was a reliable prognostic indicator in patients with AF and coronary stenting.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.